Anesiva Closes Development of 1207 Anesthetic Based on Disappointing Study Results
SOUTH SAN FRANCISCO, Calif.-- Biopharmaceutical company Anesiva Inc. said an early stage study of its topical anesthetic showed the drug was safe and tolerable, but failed to show any anesthetic effect.
The company said it will cease development of the drug, called 1207, based on the results of the Phase I clinical trial, which involved 24 healthy adult males. The drug was aimed at treating neuropathic pain.
Anesiva said it will continue to focus on its other developing pain treatments Zingo and 4975.
Shares of Anesiva fell 15 cents to $7.62 in morning trading on the Nasdaq. The stock has traded between $6.31 and $10.36 over the last 52 weeks.
HOW did 1207 NOT work?
1207 is a novel anesthetic with properties that provide pain relief by binding to the fast sodium channel [ion channels] on neurons responsible for transmitting pain signals from nerve endings to the brain. Specifically, 1207 binds to the fast sodium channel on both A nerve fibers responsible for transmitting immediate "adaptive pain" signals and C nerve fibers responsible for transmitting longer-term, dull, aching throbbing pain signals. By interrupting the communication channel of both A fibers and C fibers, 1207 is designed to provide effective topical pain relief with a faster onset and longer duration of action than currently marketed pain products. Potential applications for 1207 include pre-procedural use in dermatological surgery and post-surgical incision pain.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment